Mesa Laboratories posts Q3 and nine-month results update

Mesa Laboratories, Inc. filed a current report to let investors know it has released financial results.

(Moderate)

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

8-K

Rhea-AI Filing Summary

Mesa Laboratories, Inc. filed a current report to let investors know it has released financial results. On February 3, 2026, the company issued a press release covering its performance for the three and nine months ended December 31, 2025.

The press release is included as Exhibit 99.1 and is provided as supplemental information. The company specifies that this earnings information is being furnished, not filed, which means it is not subject to certain liability provisions of the securities laws or automatically incorporated into other securities offerings.

8-K Event Classification

2 items: 2.02, 9.01

2 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Mesa Laboratories, Inc. (MLAB) disclose in this 8-K filing?

Mesa Laboratories disclosed that it issued a press release with financial results for the three and nine months ended December 31, 2025. The press release is attached as Exhibit 99.1 and is provided as supplemental, furnished information.

Which period do Mesa Laboratories’ latest reported results cover?

The results discussed by Mesa Laboratories cover the three and nine months ended December 31, 2025. These time frames indicate both the recent quarter and the year-to-date performance through that date, as summarized in the attached press release.

How does Mesa Laboratories treat the earnings information in this 8-K?

Mesa Laboratories states the earnings information in Item 2.02 and Exhibit 99.1 is furnished, not filed, under securities laws. This treatment limits certain legal liabilities and prevents automatic incorporation into registration statements or other Securities Act documents.

Where can investors find Mesa Laboratories’ detailed quarterly results?

Investors can find detailed quarterly and nine-month results for Mesa Laboratories in the press release attached as Exhibit 99.1. The 8-K notes that this exhibit contains the company’s financial information for the period ended December 31, 2025.

Who signed Mesa Laboratories, Inc.’s February 3, 2026 8-K report?

The 8-K report was signed on behalf of Mesa Laboratories, Inc. by Gary M. Owens. He is identified in the filing as the company’s President and Chief Executive Officer, acting as the duly authorized signatory.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 02/03/2026 - 08:00 AM EST

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): February 3, 2026

MESA LABORATORIES, INC.
(Exact name of registrant as specified in its charter)

Colorado	0-11740	84-0872291
(State or other jurisdiction of incorporation)	(Commission File Number)	(I.R.S. Employer Identification No.)

12100 West Sixth Avenue,

Lakewood, Colorado
(Address of principal executive offices)

80228
(Zip Code)

Registrant’s telephone number, including area code: 303-987-8000

Not Applicable
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered under Section 12(b) of the Act:

Title of each class	Trading Symbol	Name of each exchange on which registered

Common Stock, no par value	MLAB	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

ITEM 2.02

RESULTS OF OPERATIONS AND FINANCIAL CONDITION

On February 3, 2026, Mesa Laboratories, Inc. issued a press release relating to its results for the three and nine months ended December 31, 2025. A copy of the press release is furnished herewith as Exhibit 99.1.

The information furnished in Item 2.02 of this Current Report on Form 8-K and Exhibit 99.1 attached hereto shall not be deemed to be filed for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to liabilities of that section, and shall not be deemed to be incorporated by reference into any registration statement or other document filed pursuant to the Securities Act of 1933, as amended.

ITEM 9.01

FINANCIAL STATEMENTS AND EXHIBITS

(d)

Exhibits:

99.1

Press release dated February 3, 2026.

104

Cover Page Interactive Data File (embedded withing the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

DATE: February 3, 2026		Mesa Laboratories, Inc.
		(Registrant)


	BY:	/s/ Gary M. Owens
		Gary M. Owens
		President and Chief Executive Officer

Source: View Original Filing on SEC EDGAR